Beyond these established therapeutic targets, accumulating evidence from preclinical studies and comprehensive reviews reveals that the NOTCH (4), Wnt/β-catenin (5), PI3K/AKT (6), pathway are aberrantly activated in HCC. The gene discussed is AKT1; the disease is hepatocellular carcinoma.